{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-019282","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.311181+00:00","generated_at":"2026-06-25T21:41:17.703643+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xenon Q1 net loss $19.7M; XEN1101 Phase 3 on track for H2 2022","bullets":["Net loss $19.7M vs $15.8M YoY; revenue $8.8M, up from $4.4M on Neurocrine milestone.","Cash $537.9M, sufficient to fund operations into at least 2024.","XEN1101 Phase 2b met primary endpoint; FDA End-of-Phase 2 meeting Q2 2022; Phase 3 start H2 2022.","Phase 2 X-NOVA for MDD initiated; topline results expected in 2023.","XEN496 Phase 3 EPIK in KCNQ2-DEE ongoing; completion anticipated in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-019282","json":"https://secwatch.observer/filing/0001564590-22-019282.json","markdown":"https://secwatch.observer/filing/0001564590-22-019282.md","text":"https://secwatch.observer/filing/0001564590-22-019282.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000156459022019282/0001564590-22-019282-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000156459022019282/xene-8k_20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:41:17.703643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}